Swiftsure International Inc.
Holmes Biopharma : Letter Of Intent – Drug Acquisition

Holmes Biopharma Inc. / Letter of Intent

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Holmes Biopharma : Letter Of Intent  -  Drug Acquisition 

July 10, 2007 – (Scottsdale, Arizona)  Holmes Biopharma Inc. (Berlin Stock
Exchange symbol HHJA, security code A0KDRX) is  pleased to announce that it
has signed a Letter Of Intent  to acquire the worldwide license for an
existing drug with a new and much better delivery system, now in late Phase
II stage of development.

The drug treats Ulcerative Colitis and Crohn’s disease, known collectively
as inflammatory bowel disease (IBD) that currently affects 0.5-1% of the
Western world’s population. This translates to over one million people in
America (525,000 Ulcerative Colitis, 490,000 Crohn's Disease) and four
million people worldwide ( in comparison the incidence of Brain Cancer  in
the USA  is 17,000 cases annually).  Because IBD is chronic and typically
has an onset before 30 years of age, patients generally require lifelong
treatment. Datamonitor estimates IBD to be a $1.3 Billion market in 2002,
growing to $2.3 Billion by 2010.

About Holmes:
Holmes Biopharma Inc. is a contract research organization focused on
providing
integrated and cost effective clinical development services. Holmes is also
actively involved in developing new drugs and delivery systems. For more
information about the company please visit our website at
www.holmesbiopharma.com.

On behalf of the Board of Directors 

John F. Metcalfe, President

Certain statements in this press release constitute 'forward looking
statements' within the meaning of the United States Securities Legislation.
The Company's actual results could differ from those in the forward-looking
statements. Do not construe this information as investment advice. This is
not a solicitation to buy or sell securities. This does not purport to be a
complete analysis of the Company. Investing in securities is speculative
and carries a high degree of risk. Past performance does not guarantee
future results. Readers should consult their own independent advisers with
any investment, including any contemplated investment. All information
contained in this press release should be independently investigated. This
press release contains forward-looking statements. These remarks involve
risks and uncertainties.  Risks are not limited to quarterly fluctuations
in results or the companies’ management of growth and competition. Other
risks are detailed in the Company's SEC filings.  Actual results may differ
materially from such information set forth herein.

Contact:

Holmes Biopharma, Investor Relations
Tel: 001-877-241-4779 Email: ir@holmesbiopharma.com
www.holmesbiopharma.com
DGAP 10.07.2007 
----------------------------------------------------------------------